The number one goal at Baylor’s Mesothelioma Treatment Center (MTC) is to provide the best care that is available to pleural mesothelioma patients. MTC is located in Houston, Texas and treats patients from all over the United States and from many foreign countries.

Dedicated Mesothelioma Treatment Center

The Mesothelioma Treatment Center was founded by Dr. David Sugarbaker as part of the new Lung Institute at Baylor College of Medicine. Dr. Sugarbaker is recognized as one of the top surgeons in America for pleural mesothelioma. He has over 30 years of experience and has helped thousands of mesothelioma patients.

“The medical team at the Mesothelioma Treatment Center has developed novel delivery systems for chemotherapy agents to offer patients cutting edge, surgically-based therapies for this devastating disease. By working together as one team, we bring a wealth of expertise to each patient treated at the Lung Institute,” Dr. Sugarbaker said.

Patients at the Mesothelioma Treatment Center receive personalized treatment from Dr. Sugarbaker and his team of specialized mesothelioma physicians. The physicians are dedicated to improving the outcome of patients by discovering new surgical techniques and by being actively engaged in clinical research.

Mesothelioma Treatment Center’s Latest Clinical Trials

The Mesothelioma Treatment Center conducts clinical trials that involve new treatments, pharmaceuticals, and procedures. Recently, the facility announced two clinical trials that are making great progress towards combatting mesothelioma.

  • Combining Immunotherapy With Surgery

    Baylor recently announced a new clinical trial that combines the use of immunotherapy and surgery. Researchers hope that by combining the power of the immune system and surgery, that they will be able to successfully fight mesothelioma.

    “This trial is one of the first of its kind in which immunotherapy is given before surgery, and from it, we expect to learn an enormous amount about this disease.” said Dr. Bryant Burt, an assistant professor of surgery at Baylor and the principal investigator of this clinical trial.

    At the beginning of the clinical trial, a participant will be biopsied. One to two weeks after their biopsy, a participant will either receive MEDI4736 or they’ll receive a combined therapy of MEDI4736 and tremelimumab. Two to three weeks after a participant receives immunotherapy treatment, they’ll have resectional surgery to remove their tumor(s).

    Throughout the trial, a participant’s tissue, blood, and surgically removed tumor(s) will be collected and analyzed by Baylor’s research team. Researchers hope that these samples will help them to learn more about the disease.

    Any type of histology is accepted (epithelioid, biphasic, sarcomatoid) in this clinical trial. A patient must either be chemo naive or have had no progression of their cancer after receiving 2 cycles of standard chemotherapy. Lastly, a patient must have either an extrapleural pneumonectomy or pleurectomy with decortication resectional surgery planned.

  • Targeting Mesothelin to Fight Mesothelioma

    MTC also announced a clinical trial that involves a new investigational drug to fight advanced pleural mesothelioma. This trial will analyze the safety and effectiveness of anetumab ravtansine, and compare it to the commonly used chemotherapy drug, vinorelbine.

    Researchers believe that this investigational drug might be able to slow down or stop the growth of cancer cells. Researchers have discovered that the drug anetumab ravtansine attacks a protein called mesothelin. This protein is found on the surface of mesothelioma cancer cells.

    In this trial, participants will be randomly picked for the drug that they will be given. Every three weeks some of the participants will take anetumab ravtansine. Other participants will take vinorelbine weekly.

    To qualify for this clinical trial, an individual must have completed standard chemotherapy for mesothelioma and had their cancer progress. However, an individual must not have had more than 1 previous systemic anti-cancer therapy line.

If you are interested in finding out more information about the clinical trials occurring at Baylor’s Mesothelioma Treatment Center, contact patient advocate Jenna Campagna by calling (888) 385-2024 ext. 102.

Want to learn more?

Try Our Free Guide to Fighting Mesothelioma

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

Show Sources & Author

  1. About The MTC. Mesothelioma Treatment Center. Retrieved from: http://mesotreatmentcenter.org/about-the-mtc/. Accessed: 10/13/16.
  2. Mesothelioma Treatment Center. Baylor College of Medicine. Retrieved from: https://www.bcm.edu/healthcare/care-centers/mesothelioma-treatment-center. Accessed: 10/13/16.
  3. Mesothelioma Treatment Center at Baylor St. Luke’s launches clinical trial for cancer patients. Baylor College of Medicine. Retrieved from: https://www.bcm.edu/news/lung/mesothelioma-treatment-center-clinical-trial. Accessed: 10/13/16.
  4. Study of potential new treatment for mesothelioma open to patients. Baylor College of Medicine. Retrieved from: https://www.bcm.edu/news/lung/potential-treatment-for-mesothelioma-open. Accessed: 10/18/16.
  5. MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma. ClinicalTrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02592551. Accessed: 10/27/16.
  6. Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM). ClinicalTrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02610140?term=anetumab+ravtansine&rank=4. Accessed: 10/14/16.

About the Writer, Nicole Godfrey

Nicole Godfrey is an outreach associate and contributing writer for Mesothelioma Guide. She develops content to help educate and provide awareness about the most significant information about improving a mesothelioma patient’s prognosis.